Kymera Therapeutics, Inc.

NASDAQ (USD): Kymera Therapeutics, Inc. (KYMR)

Last Price

36.88

Today's Change

+0.25 (0.68%)

Day's Change

36.36 - 37.79

Trading Volume

457,904

Overview

Market Cap

2 Billion

Shares Outstanding

64 Million

Avg Volume

488,661

Avg Price (50 Days)

40.84

Avg Price (200 Days)

41.72

PE Ratio

-15.76

EPS

-2.34

Earnings Announcement

20-Feb-2025

Previous Close

36.63

Open

36.99

Day's Range

36.36 - 37.79

Year Range

29.24 - 53.27

Trading Volume

457,904

Price Change Highlight

1 Day Change

0.68%

5 Day Change

-1.81%

1 Month Change

-15.34%

3 Month Change

-12.11%

6 Month Change

-16.26%

Ytd Change

-9.81%

1 Year Change

-1.44%

3 Year Change

-15.66%

5 Year Change

10.88%

10 Year Change

10.88%

Max Change

10.88%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment